-

Aegis Sciences Corporation Announces Updates for NPS Testing

NASHVILLE, Tenn.--(BUSINESS WIRE)--Aegis Sciences Corporation, a health care testing lab based in Nashville, TN, is pleased to announce the second bi-annual update to its novel psychoactive substance (NPS) testing menu.

"These updates equip clinicians with critical insights into emerging substances in today’s drug supply, enabling more accurate detection and informed treatment decisions. "

Share

Aegis regularly reviews and updates its NPS testing menu to maintain clinical relevance and align with recommendations from the Center for Forensic Science Research and Education (CFSRE) and the Society of Forensic Toxicologists (SOFT) NPS Committee. The latest update incorporates CFSRE’s tier one and tier two scope recommendations for Q2 2025.

CFSRE recently added two new categories to its scope recommendations: “Semi-synthetic Cannabinoids” and “Miscellaneous.” Semi-synthetic cannabinoids will now be included in Aegis’s traditional cannabinoid test, while synthetic cannabinoids will remain a separate orderable test code. Additionally, the NPS testing menu now includes Spirochlorphine (a designer opioid, also known as R6890) and Ethylbromazolam, a designer benzodiazepine found in counterfeit Alprazolam tablets.

“These updates equip clinicians with critical insights into emerging substances in today’s drug supply, enabling more accurate detection and informed treatment decisions. By identifying psychoactive compounds that may interfere with recovery, we help providers support individuals in achieving their care goals,” said Dr. Josh Schrecker, Sr. Director of Clinical Affairs at Aegis Sciences Corporation.

“Our research-driven updates demonstrate Aegis’s commitment to anticipating drug trends and expanding testing capabilities. By adding new categories and compounds, we ensure our menu reflects the evolving landscape and provides clinicians with advanced tools for comprehensive patient care,” said Dr. Rebecca Heltsley, Senior Vice President, Research and Development at Aegis Sciences Corporation.

Health care practitioners can learn more about the updated test offering at: www.aegislabs.com.

About Aegis Sciences Corporation

Founded in 1990, Aegis Sciences Corporation is a laboratory sciences company based in Nashville, Tenn., that provides science-driven testing and consulting services for clients such as health care providers, pharmaceutical companies, professional and amateur sports organizations, leading college and university athletic programs, Fortune 500 corporations, and government agencies throughout the United States. For more information, please visit http://www.aegislabs.com/.

Contacts

Stephanie Protz
Sr. Manager, Marketing Communications
stephanie.protz@aegislabs.com

Aegis Sciences Corporation


Release Versions

Contacts

Stephanie Protz
Sr. Manager, Marketing Communications
stephanie.protz@aegislabs.com

Social Media Profiles
More News From Aegis Sciences Corporation

Aegis Sciences Corporation Announces Successful $170 Million Debt Refinancing to Support Continued Growth

NASHVILLE, Tenn.--(BUSINESS WIRE)--Aegis Sciences Corporation, a leading national healthcare and forensic toxicology laboratory, today announced the successful completion of a $170 million debt refinancing, advised by CoveView Advisors. Aegis is a portfolio company of Abry Partners, a leading sector-focused North American private equity firm. In addition to contributions from new debt investors led by Kayne Anderson, Abry Partners is providing incremental growth equity capital to support Aegis’...

Aegis Sciences Corporation Announces Updates for Novel Psychoactive Substances (NPS) Testing

NASHVILLE, Tenn.--(BUSINESS WIRE)--Aegis Sciences Corporation, a health care testing lab based in Nashville, TN, is pleased to announce this year’s first bi-annual update to its novel psychoactive substance (NPS) testing menu. Aegis regularly updates its testing menu based on recommendations established collaboratively by the Center for Forensic Science Research and Education (CFSRE) and the Society of Forensic Toxicologist (SOFT) NPS Committee. Updates to the testing menu include CFSRE’s tier...

Aegis Sciences Corporation Launches MedProtectCDM to Transform Medication Adherence and Safety Monitoring for Chronic Conditions

NASHVILLE, Tenn.--(BUSINESS WIRE)--Aegis Sciences Corporation, a leading provider of innovative toxicology and healthcare testing solutions, proudly announces the launch of MedProtectCDM, a groundbreaking tool designed to enhance clinical decision-making by identifying medication nonadherence and potential drug-drug interactions. This revolutionary oral fluid-based testing solution empowers healthcare providers to optimize treatment strategies for patients receiving treatment for chronic condit...
Back to Newsroom